Total IgA and IgA reactivity to antigen I/II epitopes in HLA-DRB1*04 positive subjects

V. Wallace McCarlie1*, James K. Hartsfield Jr.2, Janice S. Blum3, Carlos González-Cabezas4, Judith R. Chin5, George J. Eckert6, Lorri A. Morford7, Mark D. Pescovitz8#, Henry Rodriguez9, Margherita Fontana4, Richard L. Gregory10*

1Department of Pediatric Dentistry and Orthodontics, School of Dental Medicine, East Carolina University, Greenville, USA; *Corresponding Author: mccarlievw@ecu.edu
2Center for Oral Health Research, Division of Orthodontics, Department of Oral Health Science, and Department of Microbiology, Immunology and Molecular Genetics, Colleges of Dentistry and Medicine, University of Kentucky, Lexington, USA
3Department of Microbiology and Immunology, School of Medicine, Indiana University, Indianapolis, USA
4Department of Cariology, Restorative Sciences and Endodontics, School of Dentistry, University of Michigan, Ann Arbor, USA
5Department of Pediatric Dentistry, School of Dentistry, Indiana University, Indianapolis, USA
6Department of Biostatistics, Schools of Medicine and Public Health, Indiana University, Indianapolis, USA
7Center for Oral Health Research, Division of Orthodontics, Department of Oral Health Science, College of Dentistry, University of Kentucky, Lexington, USA
8Departments of Surgery and Microbiology and Immunology, School of Medicine, Indiana University, Indianapolis, USA
9Department of Pediatrics, College of Medicine, University of South Florida, Tampa, USA
10Departments of Oral Biology and Preventive and Community Dentistry, and Department of Pathology and Laboratory Medicine, Schools of Dentistry and Medicine, Indiana University, Indianapolis, USA; *Corresponding Author: rgregory@iu.edu

Received 24 May 2013; revised 23 June 2013; accepted 7 July 2013

Copyright © 2013 V. Wallace McCarlie et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Bacterial adherence to the acquired dental pellicle, important in dental caries (caries), is mediated by receptor-adhesins such as salivary agglutinin binding to Streptococcus mutans antigen I/II (I/II). Ten selected I/II epitopes were chosen to determine their reactivity to human salivary IgA. Previous studies suggested that a specific HLA biomarker group (HLA-DRB1*04) may have differential influence of immune responses to I/II. However, it was not known whether secretory IgA (S IgA) responses to the selected epitopes from HLA-DRB1*04 positive subjects were different compared to controls, or across other caries-related factors such as total IgA (T IgA). Thirty-two total subjects were matched according to HLA type, gender, ethnicity and age. HLA genotyping, oral bacterial, immunoglobulin and antibody analyses were performed. A large observed difference emerged with regard to the natural immune reservoir of T IgA in HLA-DRB1*04 positive subjects, specifically, a 27.6% reduction compared to controls. In contrast to all other epitopes studied, HLA-DRB1*04 positive subjects also exhibited reduced reactivity to I/II epitope 834-853. HLA-DRB1*04 positive subjects exhibited lower specific S IgA activity/T IgA to 834-853 and also a lower specific reactivity to 834-853/whole cell S. mutans UA159. Furthermore, HLA-DRB1*04 positive subjects exhibited lower responses to I/II in its entirety. The large observed difference in T IgA and the 834-853 reactivity pattern across multiple measures suggest potentially important connections pertaining to the link between HLA-DRB1*04 and caries.

Keywords: Dental Caries; Streptococcus mutans; I/II; IgA; Immunomodulation; Immunogenetics; HLA-II; DRB1; DRB1*04

1. INTRODUCTION

The natural history of dental caries (caries) and development of the salivary immune response in humans is multifactorial. Although populated with certain types of oral streptococi (i.e., Streptococcus salivarius and Streptococcus mitis) as newborns, children are not infected with Streptococcus mutans permanently until anywhere from 18 to 36 months [1,2]. Permanent infection with
mutans streptococci during this period is dominated by *S. mutans* and *S. sobrinus*—cariogenic agents in caries. Permanent infection with others of the mutans group does not happen until tooth eruption begins, although we now know this can happen earlier, but colonizing numbers are lower and harder to detect until primary molars start erupting. Newborns lack significant levels of secretory IgA (sIgA), but by 12 to 24 months most children have sIgA levels similar to those found in adults.

In 2008, a study was published showing that an Iranian cohort of children with a specific human leukocyte antigen (HLA) class II allele (HLA-DRB1*04) were 10 times more likely to have early childhood caries (ECC) [3]. All 79 subjects were between the ages of 12 and 72 months, meaning they would have had time to become permanently infected with mutans streptococci and to have developed a mature level of sIgA. Their individual host antibody responses, however, could have only been as good as their “specificity and functional activity” against the pathogens [4]. The Iranian study did not analyze levels of mutans streptococci colonization or sIgA. However, it did report that of 35 children who did not have ECC, 34 of them were HLA-DRB1*04 negative. As is well known, antibodies, such as sIgA in mucosal immunity, play a major role in immunomodulation and are linked to HLA genetics because intracellular processes and antigen presentation is modulated by particular HLA class II (HLA-II) genes. HLA drives T-cell responses, which stimulates B-cell activation and IgA secretion. Not only have HLA-II alleles been immunopathogenically associated with members of the streptococcal family [5, 6], but also other infectious bacteria [7].

Animal and human studies suggest that HLA-II genes may play a role in the development of caries. Rat genes corresponding to the HLA region in humans have been found to regulate immunity against *S. mutans* [8]. One report indicated that murine genes found in the H-2 region, corresponding to the HLA region in humans, controlled serum IgG response to particular cariogenic epitopes [9]. The murine H-2 region has a marked effect on clinical caries susceptibility as well [10].

In Caucasian populations, HLA-DRB1*04 has been suggested as an allele that may increase caries susceptibility [11,12] whereas, in certain Asian and Brazilian populations, HLA-DQB1*06 may be a susceptible allele and HLA-DQB1*02 may be a protective allele in the caries process [13,14]. These agree with other reports that identical diseases may be associated with different HLA-II alleles in different populations [15,16].

Animal and human studies suggest that HLA immunogenetic interactions are important in modulating a cariogenic infection. Understanding the immunogenetic interactions between host and microbes, such as *S. mutans*, is critical in understanding caries, especially when desiring to improve prevention, diagnosis and detection, as well as therapeutic approaches.

Currently, *S. mutans* “remains prominent in most molecular genetic profiles of incipient dental disease, and thus continues to be a reasonable candidate for elimination” [17]. It also continues to remain the prototypic caries pathogen, and no other species within the oral microbiome “is yet a serious contender to *S. mutans* for a role as a worthwhile marker organism” in the caries process [18]. *S. mutans* has three surface proteins of major importance, which aid in attaching to tooth surfaces. These include glucosyltransferases (GTFs), glucan-binding proteins (GBPs), and antigen I/II (I/II). These proteins have been vaccine targets for caries. GBPs are surface-associated adhesins that play a substantial role in architectural development of the biofilm, GTFs are cell-associated and secreted enzymes, and I/II is a cell-wall anchored adhesin.

Bacterial adherence to the acquired dental pellicle, important in dental caries, can occur even when other exogenous factors such as sucrose are not present. This is mediated by receptor-adhesins, such as salivary agglutinin, binding to *S. mutans* I/II. Antigen I/II is comprised of several regions (A, V, P and C; Figure 1) that may stimulate salivary IgA reactivity in infected subjects. As mentioned, previous studies suggested that a specific HLA biomarker group (HLA-DRB1*04) may have differential influence on immune responses to I/II. However, it was not known whether secretory IgA (sIgA) responses to the ten selected epitopes from HLA-DRB1*04 positive subjects were different compared to controls. No known published study to date has assessed these questions. The goal of this study was to gain a molecular understanding of *S. mutans*-induced caries with the objective of future vaccine design and biomarker identification.

![Figure 1](image-url)

**Figure 1.** Schematic and diagramatic representations of the surface protein adhesin, antigen I/II. Antigen I/II is comprised of the following regions (and residues): the signal sequence (1-38), a pre-A region (39-120), the A-region (121-447), V-region (aa 448-839), P-region (840-983), and the C-terminal region (984-1463), and regions for anchor proteins associated with the bacterial cell wall including the LPxTG anchor region (CWA) (1464-1561). The A-region consists of four alanine-rich tandem repeats, specifically A1 (121-201), A2 (202-283), A3 (284-365), and A4 (366-447). The P-region also consists of three to four repeated regions (represented here as four) with about 35 percent proline content, including P1 (840-878), P2 (879-917), P3 (918-956), and P4 (957-983) [26,27].
to predict caries susceptibility.

2. MATERIALS AND METHODS

2.1. Bacterial Strains

*S. mutans* UA159 (ATCC 700610), NG8 and PC3370 were used in this study. The UA159 genome can be electronically accessed [access # NC_004350] [19].

2.2. Study Population

Prior to this study, all appropriate IRB approvals were secured. Subjects in this study were recruited from the TrialNet Natural History Study (TN NHS), which evaluated healthy yet at-risk for Type 1 diabetes (T1D) subjects since many of these subjects are HLA-DRB1*04 positive and HLA typing was already done. The study population was divided into two groups: the control group, an HLA-DRB1*04 negative group (n = 16), and an HLA-DRB1*04 positive group (n = 16). After completing the informed consent process, subjects were asked to provide a medical history and prescribed demographic information. Subjects who were HLA-DRB1*04 positive (as determined from genotyping during Phase 2 or 3 participation of TN NHS, or as determined by genotyping of genomic DNA from saliva collection as described at the time of the study visit) were invited to participate. Matched gender, ethnicity and age control subjects testing negative for HLA-DRB1*04 were also invited to participate.

2.3. Saliva Collection

At the time of the subject’s visit, unstimulated whole saliva was collected and stored at either −80°C (for bacterial enumeration) or −20°C (for antibody assays) until laboratory analysis. In some cases, two samples of saliva were collected (the first for antibody and bacterial analysis and the second for HLA DNA genotyping). For the subjects where DNA had already been collected and HLA sequenced through the TN NHS, and only one saliva sample was required, that sample was collected and later divided in the laboratory into two aliquots, one for bacterial analysis and the other for antibody analysis. Subjects were instructed to provide at least 5 mL of unstimulated saliva in a 50 mL sterile tube, and were timed in order to calculate a salivary flow rate. After the samples had been transferred to the laboratory and vortexed, 0.9 mL was pipetted into another vial and mixed with 0.2 mL of sterile glycerin, vortexed and stored at −80°C until bacterial analysis. The remainder of the sample was then divided into 1.5 mL aliquots for antibody analysis and stored at −20°C.

For those subjects requiring HLA genotyping (i.e., TN NHS HLA genotyping data was not available), a second sample was collected to determine if the participant was HLA-DRB1*04 positive or negative. For this purpose, 3 mL of stimulated saliva (stimulated for 2 min by chewing on paraffin) was collected with Oragene® DNA sample collection kits (DNA Genotek, Kanata, Ontario, Canada) and was stored at room temperature.

2.4. HLA Genotyping

Real-time PCR was utilized to determine group-specific HLA-DRB1 alleles on the Roche® LightCycler® 480 (Roche Diagnostics Corporation, Roche Applied Science, Indianapolis, IN) in the Hereditary Genomics Laboratory at the University of Kentucky. PCR was carried out as previously described [20]. Briefly, each PCR reaction (10 µl) contained: 10 ng of genomic DNA; 1X of LightCycler480® FastStart DNA Master Hybridization Probes mix (Roche Diagnostics Corporation); 200 nM HLA-DRB1*04 specific forward primer (5’-GT TTC TTT GAG CAG GTT AAA C-3’); tailed with M13F-21 (5’-GTA AAA CGA CGG CCA G-3’); 200 nM DRB-3i reverse primer (5’-C TCG CCI CTG CAC IGT IAA GC-3’ where I = inosin) tailed with the M13 reverse sequence (5’-CAG GAA ACA GCT ATG AC-3’); 200 nM HLA-DRB-specific fluorogenic probe (5’-FAM-labeled-CGG GCG GTG ACG GAG CTG GG C-Black Hole Quencher-3’); and PCR Boost (Biomatrica, Inc., San Diego, CA). All oligonucleotides were synthesized by Integrated DNA Technologies (IDT; Coralville, Iowa). The RT-PCR cycling consisted of the following steps: a) initial denaturation for 10 minutes at 95°C; b) 10 cycles of 95°C for 5 seconds and 65°C for 20 seconds with a single fluorescence reading (456 - 510 nm); c) 25 cycles of 95°C for 5 seconds and 60°C for 20 seconds with a single fluorescence reading; then d) 40°C for 30 seconds cool down. Three cell lines (courtesy of Dr. Janice S. Blum), known to be homozygous for HLA-DRB1*0401 (Priess human B cell line), heterozygous for HLA-DRB1*04/HLA-DRB1*01 (Frev B cell line), and negative for HLA-DRB1*04 (Sweig, Epstein-Barr virus (EBV) immortalized lymphoblastoid (LCL) B cells; homozygous for HLA-DRB1*1101), were used as controls.

2.5. Bacterial Analyses

Aliquots of whole saliva in glycerin were diluted 1:100 and 1:1000 in sterile saline, double-plated on Mitus Salivarius agar supplemented with sucrose and bacitracin (MSSB) (Anaerobe Systems, Morgan Hill, California). The plates were incubated for 48 hours at 37°C and 5% CO₂, and subsequently the number of mutants streptococci colonies enumerated using an automated colony counter (Protocol Synoptic LTD, North Cambridge, United Kingdom), yielding mutants streptococci colony-forming
units/mL (CFU/mL) of whole saliva.

2.6. Selecting, Synthesizing, and Storing I/II Peptides

Ten antigen I/II peptides that induce immune responses in humans, encompassing several regions of the intact protein (Figure 1) were selected for analysis based on immunoreactivity from other studies [21,22]. The following peptides were selected:

NAKATYE-AALKQYEDLAAVKKAANAA (361-386), IETGKKPNIWYSLNGKIRAV (803-822), VPKVTKKEKPTPPVKTAPTK (824-843), PPVKTPTPKTYPYETEKPLK (834-853), ETEKPLEAPVPEPSYAEAPT (925-944), PTVHFHYFKLAVQPQVNKEI (985-1004), RNNNINDRTLVAQSVVVK (1005-1024), FQLKTADLPAGDGETSFVL (1025-1044), TLATFNADLTKSVAITPTV (1085-1104), and KSVATYPTVUVGVLNDGAT (1095-1114). These peptides derived from the A-region (121-447), V-region (448-839), P-region (840-983), and the C-terminal region (984-1463), respectively. Each peptide was synthesized (Peptide 2.0, Chantilly, Virginia) and lyophilized at the following purities (following the same order as above, in percent): 91.1, 92.2, 96.9, 98.0, 95.1, 96.6, 93.6, 80.6, 79.4, and 93.2. Each peptide was dissolved in distilled water to yield a 1 mg/mL stock solution and stored at −20°C.

2.7. Enzyme-Linked Immunosorbent Assay (ELISA)

Total IgA, levels of salivary IgA (SIgA) antibodies to I/II epitopes of S. mutans UA159, and whole cells of S. mutans (UA159, NG8 and I/II-deficient PC3370 on an NG8 background) were detected using ELISA. Briefly, the total level of IgA (TlIgA) in saliva was determined by a sandwich ELISA, as follows. Goat anti-human IgA (Sigma Chemical Co., St. Louis, Mo.) was used as the coating antibody and horseradish peroxidase (HRP)-labeled goat anti-human IgA (Sigma, alpha chain specific) was used as the detecting antibody as previously described [23]. The plates were read on a SpectraMax 190 microplate spectrophotometer (Molecular Devices, Sunnyvale, California) at 490 nm. IgA standards were used to calculate the unknown IgA sample values by linear regression analysis. Calculations were performed by using the standard curve equation from a log-log function (R² = 0.991). Total IgA determinations were accomplished by creating a standard curve from standard concentrations of human colostral IgA (Sigma: 200 to 0 μg/mL).

A modified ELISA [24] was used to measure human SlgA binding to the ten I/II peptides (1 μg/mL) and 3 formalin-killed strains of S. mutans (UA159, NG8 and an NG8-derived antigen I/II deficient mutant strain PC3370). For the latter assays, lysed whole S. mutans cells were used in place of I/II epitopes. Data was also reported as a ratio of each peptide value divided by the total IgA concentration or reactivity to the three S. mutans whole cell antigens.

2.8. Data Analysis

All experiments were done in either duplicate or triplicate and are reported as means and standard errors of the mean. Paired t-tests were used to compare the matched pairs from the HLA-DRB1*04 positive and control groups. A natural logarithmic transformation of the variables was used for most analyses due to the non-normal distribution of the data.

3. RESULTS

Figure 1 represents antigen I/II and the varying locations of the 10 epitopes tested. Previous work has demonstrated that these epitopes are either human salivary IgA targets or elicit varying degrees of human T- and B-cell responses. HLA drives T-cell responses, which stimulates B-cell activation and IgA secretion.

HLA-DRB1*04 (hereafter, DRB1*04) positive subjects did not exhibit statistically significant differences in levels of S. mutans (Figure 2).

Total IgA levels in DRB1*04 positive subjects were lower by 27.6% (Figure 3), and although not statistically significant, this observed difference has never been reported. This means that, on average, DRB1*04 positive subjects have 25 μg/mL less TlIgA compared to their negative counterparts. The concentrations of TlIgA in all subjects ranged from 15.3 - 420.4 μg/mL, in agreement with a recent report demonstrating TlIgA concentrations ranging from 13.7 - 483.0 μg/mL in 134 healthy individuals [25]. The average control subject exhibited a TlIgA concentration of 89 μg/mL whereas the DRB1*04 positive subject had 64 μg/mL of TlIgA.

DRB1*04 positive subjects also exhibited numerically, but not statistically, higher specific immunoreactivity to nine out of 10 epitopes compared to controls (Figure 4). However, DRB1*04 positive subjects exhibited lessened reactivity to epitope 834-853, though not statistically significant. This epitope’s amino-terminus straddles the carboxy-terminus of the V region of I/II, and the epitope’s carboxy-terminus encompasses most of the P1 region, which appears to be a very important interface between all three (A, V, and P) I/II regions. Though not statistically significant, DRB1*04 positive subjects exhibited lower specific SlgA activity/TlIgA to 834-853, and also a lower reactivity ratio of 834-853/whole cell S. mutans UA159 (Figure 5). In an indirect measure of immunoreactivity against the entire I/II antigen (PC3370...
Figure 2. The log transformed number of *S. mutans* colony forming units/mL of whole saliva for DRB1*04 positive (n = 16) and negative subjects (n = 16). These data are reported as natural log means and standard errors of the mean.

Figure 3. Human salivary total IgA among HLA-DRB1*04 positive (n = 16) and negative subjects (n = 16).
Figure 4. Human salivary IgA specific activity of HLA-DRB1*04 positive (n = 16) and negative subjects (n = 16) to 10 selected putative epitopes of *S. mutans* I/II. Specific activity was calculated using the natural log of the ratio of each subject’s SIgA OD reading for each epitope in triplicate to the total IgA OD for each subject. These data are reported in natural log values as means and standard errors of the mean.

Figure 5. Human salivary IgA reactivity ratios of HLA-DRB1*04 positive (n = 16) and negative subjects (n = 16) to 10 selected putative epitopes of *S. mutans* I/II/S. *mutans* UA159 whole cells (UA159). These data are reported in natural log values as means and standard errors of the mean.
background devoid of antigen I/II subtracted from the NG8 wildtype strain containing an intact antigen I/II), DRB1*04 positive subjects exhibited lower responses, though not statistically significant. This suggests that when encountering the entire antigen, in contrast to the selected peptides, these DRB1*04 positive subjects were not able to respond as well as controls (Figure 6).

4. DISCUSSION

The goal of this study was to gain a molecular understanding of *S. mutans*-induced caries with the goal of future vaccine design and biomarker identification to predict caries susceptibility. Previous literature suggested that HLA-DRB1*04 appears to be a caries susceptibility allele in Caucasians. Our current results do not disprove this notion, but argue for a more nuanced and complicated picture regarding the immunogenetics of caries development.

Consistent with the link between DRB1*04 and caries, this study revealed a large reduction in TIgA of DRB1*04 positive subjects (27.6%) compared to controls (Figure 6). Though the TIgA difference was not statistically significant, the large observed difference may prove clinically important, both to mucosal immunity and caries specifically. Less TIgA putatively leads to a decreased ability to respond to cariogenic organisms.

Also in agreement with the link between DRB1*04 and caries, DRB1*04 positive subjects exhibited reduced reactivity to a single epitope in this study, 834-853. Though this observed difference was not statistically significant, the fact that this difference occurs across multiple measures suggests that it may be both biologically and clinically important (Figures 4-6). This research needs to be examined in a larger population to verify the differences observed in this study. Future research is necessary to determine if vaccination to this epitope might boost caries immunity since, among other things, 834-853 is crucially involved in a primary gp340 binding domain.

Results suggest that DRB1*04 positive subjects exhibit a lower SIgA response to I/II of *S. mutans* NG8 compared to controls (Figure 6). This yet suggests that I/II is important but that the selected epitopes do not account for all immunoreactivity. Both GTFs and GBP also play an important role in caries development. Researchers have hypothesized that HLA-II alleles produce...
Copyright © 2013 SciRes.
the P region and the carboxy terminus of the A region) initially adheres to the salivary pellicle, the distal arm can flex to such a degree that the C-terminal domain, which abuts the anchor motif on S. mutans itself, can actually bind gp340 as well. Thus, if host SlgA sufficiently responds to this very particular region, I/II will not be able to take advantage of these binding sites and the process of caries will be abated or slowed. Alternatively, if there were low SlgA responses to this particular epitope located in the distal arm region, it would follow that I/II could take full advantage of its array of virulent mechanisms, which fits the hypothesis with regard to the DRB1*04 positive group and the epitope found at 834-853. That the control group may exhibit a better ability to naturally fight caries while still in its early stages is supported by the fact of higher reactivity to the 834-853 epitope.

Ultimately, however, how antibodies relate to their HLA gene-encoding counterparts remains to be fully explored. As these fundamental mechanisms become better understood in the long-term [18], our ability to design vaccines will not only increase but also enable us to individually tailor immunizations. Caries is also affected in large part by exogenous variables such as oral hygiene, diet, fluoride exposure, as well as psycho-social factors, all of which may change over time in different ways. If a larger and more comprehensive study confirms what is observed in this study, it will also be necessary to control, to the extent possible, other environmental variables such as those mentioned.

5. CONCLUSION

These results show that DRB1*04 positive subjects have an observed reduction in TlAg compared to controls, an observational difference never before published. Also, it demonstrates that a particular epitope may play a significant role in the caries process depending on the immune status of the host. This epitope (834-853) located in the distal arm of the V region (also connected to the P1 region) is probably very important, and provides a biological connection between reduced SlgA reactivity in DRB1*04 positive subjects to its binding site, and therefore greater adherence to the tooth structure, which can lead to caries.

6. ACKNOWLEDGEMENTS

Support in subject accrual and data acquisition for this study was provided by the Type 1 Diabetes TrialNet Study Group at Riley Hospital NIH U01DK085505. Type 1 Diabetes TrialNet Study Group is a clinical trials network funded by the National Institutes of Health (NIH) through the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute of Allergy and Infectious Diseases, and The Eunice Kennedy Shriver National Institute of Child Health and Human Development, through the cooperative agreements U01 DK061010, U01 DK061016, U01 DK061034, U01 DK061036, U01 DK061040, U01 DK061041, U01 DK061042, U01 DK061055, U01 DK061058, U01 DK084565, U01 DK085453, U01 DK085461, U01 DK085463, U01 DK085466, U01 DK085499, U01 DK085505, U01 DK085509, and a contract HHSN267200800019C; the National Center for Research Resources, through Clinical Translational Science Awards UL1 RR024982, UL1 RR025744, UL1 RR025761, UL1 RR025780, UL1 RR029890, UL1 RR031986, P30 DK017047, and General Clinical Research Center Award M01 RR00400; the Juvenile Diabetes Research Foundation International (JDRF); and the American Diabetes Association (ADA). The contents of this Article are solely the responsibility of the authors and do not necessarily represent the official views of the NIH, JDRF, or ADA.

This work was supported by an Indiana Clinical and Translational Science Institute (CTSI) award to V.W.M. Some research supplies were also procured with financial support from the Department of Orthodontics and Orofacial Genetics, courtesy of Dr. Kula. The Oral Health Research Institute faculty, staff, and its director, Dr. Zero, provided excellent research infrastructure. Special thanks go to Sue Kelly, Susan Hayden, Sharon Gwinn, Lorena del Carmen Galvez, Jodie Jarrett, Jen Tran, Cunge (Ellen) Zheng and Amir Haider. The two mutant strains, NG8, and an NG8-derived I/II-mutant strain, PC3370, were kindly provided by Dr. L. Jeannine Brady in the Department of Oral Biology, at the University of Florida, Gainesville, Florida.

REFERENCES


